{"id":390506,"date":"2018-12-26T00:00:00","date_gmt":"2018-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2018-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-14T10:26:05","modified_gmt":"2026-04-14T10:26:05","slug":"dlsfid0001-2018-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2018-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Gram-Negative Infections | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (<abbr data-original-title=\"gram-negative pathogen\" title=\"\">GNP<\/abbr>s). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already limited gram-negative infection (<abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>) armamentarium. Despite the launch of antibiotics such as Avycaz\/Zavicefta, Zerbaxa, and Vabomere, unmet needs remain for additional effective treatment options. There are commercial opportunities for emerging therapies with efficacy in patients with drug-resistant infections, especially those associated with high rates of mortality. However, the market is heavily genericized, and cost-containment measures may limit commercial success.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the drivers and constraints in the\u00a0<abbr data-original-title=\"hospital-treated\" title=\"\">HT<\/abbr>&#8211;<abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>\u00a0market, and how will the market evolve over the forecast period? How will rising antibiotic resistance rates and entry of new generics shape the market?<\/li>\n<li>How large are the different\u00a0<abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>\u00a0indications? What are the resistance rates to different classes of antibiotics across several pathogen species?<\/li>\n<li>How will emerging therapies such as Merck\u2019s imipenem\/cilastatin\/relebactam, Achaogen\u2019s plazomicin, Tetraphase\u2019s eravacycline, or Shionogi\u2019s cefiderocol address current unmet needs? What emerging therapies do\u00a0<abbr data-original-title=\"infectious disease\" title=\"\">ID<\/abbr>\u00a0specialists consider the most promising?<\/li>\n<li>What attributes will emerging therapies need to improve on to compete with currently marketed products?<\/li>\n<\/ul>\n<p><abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>s account for a large portion of hospital-treated infections (<abbr data-original-title=\"hospital-treated infection\" title=\"\">HTI<\/abbr>s), which represent a high-value segment of the antibacterial market given the severity of these infections. In the past, developers have focused heavily on anti-gram-positive therapies, such as those against methicillin-resistant\u00a0<em>Staphylococcus<\/em><em>\u00a0aureus<\/em>\u00a0(<abbr data-original-title=\"methicillin-resistant Staphylococcus aureus\" title=\"\">MRSA<\/abbr>), which has allowed the number of antibiotics for\u00a0<abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>s in the late-stage pipeline to dwindle. Therefore, the\u00a0<abbr data-original-title=\"gram-negative infection\" title=\"\">GNI<\/abbr>\u00a0market provides wide market opportunity for developers that can tackle segments of unmet need. In particular, rising multidrug resistance in key\u00a0<abbr data-original-title=\"gram-negative pathogen\" title=\"\">GNP<\/abbr>s (e.g.,\u00a0<em>Pseudomonas aeruginosa<\/em>,\u00a0<em>Acinetobacter baumannii<\/em>,\u00a0<em>Escherichia coli<\/em>, and\u00a0<em>Klebsiella pneumoniae<\/em>) leaves physicians with limited therapeutic options. With fewer alternatives, high-volume use of several current agents creates selective pressure for the further development of drug resistance to therapy. Thus, opportunity exists for developers that can provide therapies to not only overcome drug resistance to current treatments but that are safe and tolerable and can stave off the emergence of antibiotic resistance by using novel mechanisms of action.<\/p>\n","protected":false},"template":"","class_list":["post-390506","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hospital-treated-infections","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390506\/revisions"}],"predecessor-version":[{"id":393630,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390506\/revisions\/393630"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}